Which of the following is a common phosphate binder used in treatment?

The most appropriate choice for a common phosphate binder used in the treatment of hyperphosphatemia in patients with chronic kidney disease is Calcium Carbonate. Calcium Carbonate acts by binding phosphate in the gastrointestinal tract, preventing its absorption and helping to lower serum phosphate levels.

While Aluminum Hydroxide can also be used as a phosphate binder, its use has declined due to potential toxicity and adverse effects associated with aluminum accumulation, particularly in patients with renal impairment. Zemplar is primarily used as a vitamin D analogue to help manage secondary hyperparathyroidism, not as a phosphate binder. Vitamin D itself is crucial for promoting calcium absorption but does not bind phosphate. Thus, Calcium Carbonate remains the standard and most commonly used phosphate binder in clinical practice for managing phosphate levels in patients undergoing hemodialysis.